secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040701
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Q3 EsoGuard rev $783K (+392% seq.), net loss $14.2M
---------------------------------------------------------

- EsoGuard test volume 2,575 (17% sequential increase, 137% YoY).
- EsoGuard revenue $783K, up 392% sequentially and 930% YoY; net loss $14.2M ($0.34 per share).
- Non-GAAP adjusted loss $9.3M ($0.22 per share); cash $24.1M vs $32.6M at June 30.
- Clinical utility data: near-perfect concordance from three studies totaling over 1,500 patients.
- EsoGuard 2.0 launched with multiplexed triplicate consensus; NGS platform upgrade underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/0001493152-23-040701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer